-
Bladder cancer is heavy! EU approves Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!
Time of Update: 2021-03-04
that in all two major groups of randomly grouped patients and tumor PD-L1-positive patients, bavencio-BSC first-line maintenance therapy significantly extended total survival (OS) and significantly increased one-year survival rates compared to Best Support
-
Regret! Pharmaceutical giant Merck has become the first multinational drugmaker to announce it is abandoning research and development of the COVID-19 vaccine
Time of Update: 2021-03-04
In early 2020, the new coronary pneumonia (COVID-19) outbreak caused by the new coronavirus (SARS-CoV-2) spurred a major step forward in global drug and vaccine research and development, and in less than a year, new crown vaccines developed
-
Merck's Bavencio meets mid-term analysis of bladder cancer
Time of Update: 2021-03-03
New data from the JAVELIN Bladder 100 Phase III study show that bavencio (avelumab) reached the primary endpoint of its overall survival rate (overall survival) in the planned midterm analysis, which was previously untreated for locally
-
Germany Merck 2019 q3 performance bright future will continue to grow!
Time of Update: 2021-03-02
The life sciences business grew 12.3 per cent year-on-year to EUR 1.72 billion, while sales of high-performance materials fell 6.9 per cent year-on-year to EUR 583 million.
-
Merck has cut more than 200 jobs in France and sold its factories
Time of Update: 2021-03-02
layoffs of about $1.2 billion, about 55 percent of which would be compensation costs and the rest would be accelerated depreciation of facilities to be closed or divested. same time, the company is building a new plant in Ireland that plans to hire 350 people to produce Keytruda and 425 to increase Gardasil's production in the United States. （cyy123.com）
-
Merck enhances the manufacturing capabilities of commercial virus vectors and gene therapy products
Time of Update: 2021-03-01
the key to Merck's technological progress. That's why Merck has evolved since it was founded in 1668. The founding family still holds a majority stake in the publicly traded company. Merck owns the name and brand worldwide, with the exception
-
Merck Pharma holding hands with Ali Health Path-to-Road Pharmaceutical e-commerce
Time of Update: 2021-02-28
the people's growing multi-level diversified medical and health needs, in April this year, the General Office of the State Council issued the Opinions on Promoting the Development of "Internet plus Medical Health", which is another heavyweight top-level
-
Merck has joined the big drug pricing commitments - but sceptics don't believe it
Time of Update: 2021-02-22
comes after Pfizer and Novart recently announced they would freeze price increases for the rest of the year, a small trend after Trump and Pfizer CEO Ian Reid made a lengthy phone call last week about drug prices.
-
Merck continues to invest additionally in China to accelerate the ® one-time technology products in Wuxi
Time of Update: 2021-02-20
, a leading technology company, announced that it would continue to invest more in China to speed up the ® of Mobius's single-use technology products in Wuxi, the company said in a news report.
-
Pfizer and Merck terminated Bavencio's Phase III study
Time of Update: 2021-02-17
JAVELIN Ovarian PARP 100 studies and early stage studies are still under way to study drugs in a variety of combinations.
-
First-line treatment of advanced kidney cancer! Pfizer/Merck Immunity and Targeting Group Bavencio and Inlyta performed strongly
Time of Update: 2021-02-16
%CI:0.42-0.74) and the duration of the remission increased by 4 months (95% CI:2.9-5.1). The consistency of PFS and ORR observed so far in all patients, including subgroups, suggests that many different types of patients, including those
-
Merck Unveils New Pigment Candurin NXT Ruby Red
Time of Update: 2021-02-15
non-artificial, vegetarian and Jewish certified new effect pigment Candurin NXT Ruby Red is an insoluble combination of silicon and iron oxide.
-
Merck: Solid growth in the first quarter in the biopharmaceutical sector
Time of Update: 2021-02-13
In the first quarter of 2015, the Pharmaceutical and Health business achieved an organic sales growth of 0.3%. Overall net sales rose 7.4% to EUR 1.7 billion (Q1 2014: EUR 1.6 billion), including a positive foreign exchange impact of 7.1%. Organic
-
Dual-functional immunotherapy! The FDA awarded Merck TGF-β/PD-L1 dual-target therapy M7824 to treat bile duct cancer orphans.
Time of Update: 2021-02-12
BTC treatment options are limited, the medium survival of late-stage patients is less than 1 year, the objective tumor mitigation rate for common chemotherapy is usually less than 10%, and the remission time is short.
-
The FDA today accelerated the approval of Merck MET inhibitors in Germany for the treatment of specific patients with non-small cell lung cancer
Time of Update: 2021-02-10
Tepmetko provides an important new treatment option for patients with metastasis NSCLC who carry these gene variants.
-
Merck/GSK terminated the M7824 phase 3 head-to-head study of the treatment of lung cancer in Keytruda, Bethesda
Time of Update: 2021-01-30
On January 20th Merck KGaA, the German pharmaceutical giant, announced the latest developments in the study of bintrafusp alfa (M7824) lung cancer Phase 3 INTR@PID Lung 037 and updated the INTR@PID clinical trial project.
-
Bladder cancer is heavy! EU CHMP recommends approval of Merck/Pfizer immunotherapy Bavencio
Time of Update: 2020-12-27
with localized advanced or metastatic urethroid skin cancer (mUC), specifically: (1) patients with progression during or after platinum chemotherapy; June, based on the results of a validated Phase 3 JAVELIN Bladder 100 study, the FDA approved
-
The European Union will review Merck's lung cancer-targeted drug Tepotinib
Time of Update: 2020-12-14
Tepotinib is designed to treat advanced non-small cell lung cancer (NSCLC) in adults with the interstumin-epithortic conversion factor gene (MET) exon 14 (METex14) jump mutation.
-
Merck, IAVI and the Indian Serum Research Institute have collaborated in the development of COVID-19 monoclonal antibodies.
Time of Update: 2020-10-30
German pharmaceutical company Merck KGaA, the non-profit research organization IAVI and the Indian Serum Research Institute have collaborated to develop monoclonal antibodies (mAb) for COVID-19.
-
IDWeek 2020: Merck will demonstrate its extensive anti-infector drug development pipeline.
Time of Update: 2020-10-28
Merck today announced that clinical data from its extensive infectious disease and vaccine program will be published in IDWeek 2020 from October 21 to 25, 2020.
